Millennium Management
GALT icon

Millennium Management’s Galectin Therapeutics GALT Stock Holding History

Millennium Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-87,000
Closed -$1.33M – 3573
2014
Q1 		$1.33M Buy
+87,000
New +$1.24M ﹤0.01% 2056

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management's GALT Position: Q1 2026 in Review

Millennium Management increased its Galectin Therapeutics (GALT) stake by 239% in Q1 2026, buying an estimated $1.71M and bringing the position to 798,434 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3771.

Millennium Management first reported a position in GALT in Q1 2014 and has held it in 34 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Millennium Management held 798,434 shares of Galectin Therapeutics worth $2.23M as of Q1 2026.
  • Millennium Management bought 562,926 Galectin Therapeutics shares in Q1 2026, an estimated $1.71M.
  • Galectin Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3771 holding.
  • Millennium Management first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 34 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.